Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

RAD Share Facility Agreement of up to A$12.5m addendum

Tuesday, February 6, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced an addendum to its share facility agreement, increasing the funding capacity to A$12.5 million. This financial boost is expected to support the company's clinical studies and development efforts. Positive clinical updates across multiple programs further enhance the company's outlook.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD has secured a significant funding agreement of A$12.5 million.
  • The funding will support ongoing clinical studies and development.
  • Positive updates from Radiopharm Theranostics indicate progress in their programs.

Full Press Release Details

• Announcements
• Price Sensitive
• February 6, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• October 25, 2022
• Announcements
• October 9, 2023
• Announcements
• October 20, 2022
• Announcements
• December 15, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the amount of the new share facility agreement?

The new share facility agreement is for up to A$12.5 million.

What will the funding support?

The funding will support ongoing clinical studies and development efforts.

What company is involved in this agreement?

The agreement involves Radiopharm Theranostics.

What updates has Radiopharm provided?

Radiopharm has provided positive clinical updates across multiple programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics A$12.5 million clinical studies funding agreement
Last updated: Feb 6, 2024